Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093015
Status:
COMPLETED
Last Update Posted:
2022-11-08
First Post:
2004-09-28
Brief Title:
Trial to Reduce Cardiovascular Events With Aranesp Therapy TREAT
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
Trial to Reduce Cardiovascular Events With Aranesp Therapy
Status:
COMPLETED
Status Verified Date:
2022-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the impact of treatment of anemia with darbepoetin alfa to a hemoglobin target of 13 gdL on 1 all-cause mortality and nonfatal cardiovascular events and 2 progression to end-stage renal disease or death in subjects with chronic kidney disease and type 2 diabetes mellitus
Academic PIExecutive Committee Chairman Marc Pfeffer MD PhD
Academic PIExecutive Committee Chairman Marc Pfeffer MD PhD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| TREAT | None | None | None |